# Genmab A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Genmab A/S). ## Overview Genmab A/S is a Denmark-based biotechnology company focused on discovering and developing antibody medicines for cancer and other serious diseases. Its business spans approved therapies, partnered programs, and a pipeline of next-generation antibody formats, with international operations across North America, Europe, and Asia Pacific. ## Products & services • Approved antibody medicines and related royalties • EPKINLY net product sales and collaboration revenue • Co-development and collaboration programs with partners • Late-stage clinical antibody pipeline • Antibody formats: bispecifics, ADCs, immune-modulating antibodies - **Royalties** (82%) — Royalty income from partner sales of approved antibody medicines. - **Net product sales / collaboration revenue** (12%) — Sales of Genmab-linked products and collaboration-linked commercial revenue. - **Milestones and reimbursement revenue** (3%) — Commercial and development milestones plus R&D reimbursement from partners. - **Research and development collaborations** (3%) — Partnered discovery, development, and licensing arrangements for antibody assets. - Approved antibody medicines and related royalties - EPKINLY net product sales and collaboration revenue - Co-development and collaboration programs with partners - Late-stage clinical antibody pipeline - Antibody formats: bispecifics, ADCs, immune-modulating antibodies ## Customers Genmab sells primarily to biopharmaceutical partners, where revenue comes from royalties, product-related collaboration income, milestones, and reimbursements tied to development and commercialization agreements. Its therapeutic products ultimately serve oncology and serious-disease patients through healthcare providers, but the direct economic buyers are usually large pharma partners and licensees. The company’s model depends on the success of partner-led commercialization as well as adoption of its own product contributions such as EPKINLY. - **Pharmaceutical collaboration partners** (primary) — Large biotech and pharma companies that license, develop, and commercialize Genmab antibodies and pay royalties, milestones, or reimbursements. - **Oncology treatment providers** (primary) — Hospitals, cancer centers, and infusion clinics that administer partner-commercialized antibody medicines to patients. - **Patients with hematology/oncology indications** (secondary) — End patients benefiting from approved therapies such as antibody-based cancer medicines. - **Research and development collaborators** (primary) — Partners sharing development costs and programs in exchange for pipeline access and commercial rights. - Pharma partners that commercialize Genmab-originated antibodies - Hospitals and oncology clinics through partner-launched medicines - Collaborators funding shared development programs - Patients with B-cell malignancies and other serious diseases - Healthcare systems that use specialty oncology biologics ## Geography Genmab is headquartered in Copenhagen and operates internationally across North America, Europe, and Asia Pacific. Its economic exposure is concentrated in the U.S. through partnered oncology commercialization, while Denmark remains the corporate and R&D center. The company’s revenue base is geographically diversified through partner sales and royalty streams tied to global medicine launches. - **North America** (45%) — Major commercial and clinical development market; U.S. is especially important. - **Europe** (30%) — Corporate headquarters in Denmark and broader European operations. - **Asia Pacific** (25%) — Includes product sales and international development presence. - Headquartered in Copenhagen, Denmark - Commercial and R&D presence across North America, Europe, and Asia Pacific - U.S. is a key market for EPKINLY and oncology partner sales - Partner royalties depend on global commercial uptake - International footprint supports clinical development and talent access ## Strategy Genmab’s strategy centers on advancing antibody medicines from discovery through late-stage development and commercial partnerships, with a growing emphasis on its own and partnered oncology assets. The company is extending its platform across bispecific antibodies, ADCs, and immune-modulating formats while building a larger base of royalty and product revenue. It also relies on global partnerships to broaden commercial reach and convert pipeline programs into durable revenue streams. - **Advance epcoritamab-based programs** (short-term) — Epcoritamab is a core growth asset and can expand across multiple B-cell malignancy settings. - **Increase royalty and product revenue mix** (medium-term) — A broader mix lowers dependence on any single product and improves monetization of the antibody platform. - **Expand next-generation antibody modalities** (medium-term) — Bispecifics, ADCs, and immune-modulating antibodies deepen the pipeline and improve long-term optionality. - Expand late-stage oncology pipeline into commercial products - Grow royalty revenue from partner-launched medicines - Scale EPKINLY and other product-linked revenue streams - Advance next-generation antibody formats and combinations - Use partnerships to broaden reach and reduce single-asset dependence ## Risks Genmab depends on the clinical and commercial success of a relatively concentrated set of antibody assets and partner programs, so pipeline setbacks or slower-than-expected uptake can affect growth. Because much of revenue comes from royalties and collaboration arrangements, the company is exposed to partner execution, pricing pressure, and regulatory risk across multiple markets. As a biotech company with significant intangible assets and global operations, it also faces valuation, impairment, and foreign-exchange-related accounting and business risks. - **Concentration in a small number of oncology assets** [high] — Revenue and pipeline value rely heavily on a few approved and late-stage antibody programs. - **Clinical and regulatory development risk** [high] — Late-stage trials may fail to show efficacy or safety needed for approval and label expansion. - **Partner commercialization and pricing risk** [high] — Royalties and collaboration revenue depend on third-party launch execution, reimbursement, and pricing. - **Impairment of acquired intangibles and goodwill** [medium] — Biotech acquisition accounting can leave large asset balances sensitive to revised assumptions. - Dependence on a few antibody products and partners - Clinical trial failures could delay or eliminate future revenue - Partner commercialization affects royalty and product income - Regulatory and market-access risk in oncology markets - Intangible asset and goodwill balances may face impairment risk ## Accounting Genmab’s reporting is shaped by partnership accounting, where milestone, reimbursement, royalty, and product-split arrangements can move revenue between periods depending on performance obligations and commercial sales timing. The company also carries significant acquired intangible assets and goodwill, so estimates around useful life, fair value, and impairment matter for reported earnings and balance sheet quality. Derivative instruments and foreign-currency exposures add further volatility to interim results and comparability across periods. - **Royalty revenue recognition** — Can create quarter-to-quarter swings in reported revenue - **Contract liabilities from collaboration agreements** — Affects timing of reimbursement revenue recognition - **Acquired intangible assets and goodwill** — Can materially affect earnings if assumptions change - **Derivative financial instruments** — May add non-operating volatility to interim results - Royalty recognition depends on partner sales timing and contract terms - Milestone and reimbursement revenue can be lumpy across quarters - Contract liabilities reflect remaining R&D obligations under collaborations - Acquired intangibles and goodwill require periodic impairment testing - Derivative and FX accounting can affect interim earnings volatility --- *Last updated: 2026-09-28T12:03:42.672758+00:00*